Cagrilintide is a long acting version of amylin, a hormone your pancreas releases alongside insulin whenever you eat. Amylin is one of the body's fullness signals. It slows how fast the stomach empties and tells the brain that food has arrived.
Natural amylin breaks down in minutes, which makes it useless as a medicine. Cagrilintide is engineered to survive long enough for once weekly injection.
What makes it interesting is that it works through a different route than the GLP-1 drugs. Semaglutide and tirzepatide act on the GLP-1 pathway. Amylin is a separate fullness system, so combining the two hits appetite from two directions at once.
That combination is the real story. Novo Nordisk pairs cagrilintide with semaglutide in a single weekly injection called CagriSema, which has produced some of the largest weight loss results yet recorded in obesity trials. It was filed with the FDA in December 2025, with a decision expected in late 2026.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
No reviews yet. Be the first.
Cagrilintide has been tested both alone and in combination, and the combination is where the striking numbers come from.
On its own, Phase 3 work reported about 11.8 percent average weight reduction. That is meaningful but below what the leading GLP-1 drugs achieve by themselves.
Combined with semaglutide as CagriSema, the REDEFINE 1 trial reported 22.7 percent average weight loss at 68 weeks, against 16.1 percent for semaglutide alone in the same study. Sixty percent of participants lost at least a fifth of their body weight and 23 percent lost 30 percent or more. Eighty eight percent of those with prediabetes returned to normal blood sugar.
The head to head result deserves attention too. In REDEFINE 4, CagriSema produced 23.0 percent weight loss compared with 25.5 percent for tirzepatide. So the combination is powerful, but it did not beat the drug it was measured against.
The scientifically interesting part is the principle. Stacking two separate appetite pathways produces more than either alone, which points to where obesity treatment is heading after the GLP-1 era.